Patients' Attitudes Toward and Experiences With Buprenorphine Treatment

Opioid-Related Disorders Clinical Trial

Official title: Exploring the Attitudes and Experiences of Patients Engaged in Buprenorphine Treatment During the COVID-19 Pandemic

Status Recruiting

Clinical Trial Summary

This study will disseminate five surveys collecting individual's attitudes and experiences during buprenorphine treatment for Opioid Use Disorder during the COVID-19 pandemic.

Clinical Trial Description

The primary objective of this study is to better understand patients' attitudes and experiences during office-based opioid treatment (OBOT) in the COVID-19 pandemic. This study specifically aims to evaluate attitudes and experiences of people prescribe buprenorphine across five domains with the hope of evaluating a) whether telemedicine has improved their access to and experiences with OBOT; b) the factors that motivate individuals in OBOT to abstain from opioid drug use; c) how patients' view the use of cannabis, benzodiazepines, and nicotine during OBOT; d) the degree to which patients in OBOT report using cannabis, benzodiazepines, and nicotine and how their use might have changed during the COVID-19 pandemic; and e) whether patients attitudes towards cannabis, benzodiazepines, and cigarettes/e-cigarettes are associated with their use of those same substances. ;

Related Conditions & MeSH terms

• Acceptability of Health Care
• Opioid-Related Disorders
• Opioid-use Disorder

• NCT number: NCT05121428
• Study type: Observational
• Source: Cambridge Health Alliance
• Contact: Joseph Rosansky
• Phone: 617-575-5802
• Email: jrosansky@cha.harvard.edu
• Status: Recruiting
• Start date: November 20, 2021
• Completion date: March 20, 2025